The Role of Pharmacoeconomics in Decision Making at the Institutional Level for Speciality Drugs
Pharmacoeconomics has been used, in various ways, at the institutional level, for formulary decision making around specialty pharmaceuticals. This program reviews the role of pharmacoeconomics and cost-effectiveness thresholds, along with mechanisms that influence and affect drug policy listing decisions.
This program has received an unrestricted educational grant or in-kind support from Pharmascience.
This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for 0.50 CEUs.
Ahmad Abulaban, MBBS, SBN, CRND, MSCS, ABCN (CCEEG)
Assistant Professor of Neurology
King Saud bin-Abdulaziz University for Health Sciences
Division of Neurology, Department of Medicine
King Abdulaziz Medical City, National Guard Health Affairs
Yaser M. Al Malik, MD, FRCPC, American Board of Psychiatry and Neurology, CSCN (EEG & EMG)
Assistant professor and Consultant Neurologist
King Saud bin Abdulaziz University for Health Sciences
King Abdulaziz Medical City, Ministry of National Guard Health Affairs
Moe Abdallah, B.SC., B.SC.PHM., R.PH
Clinical pharmacist, Drug Programs Policy and Strategy Branch
Ontario Public Drug Programs
Ministry of Health and Long-Term Care
Michael Boivin, RPh, BScPhm
Clinical Pharmacist Consultant and Continuing Education Developer
After viewing this expert brief, participants will be better able to:
- Describe how pharmacoeconomics is used to make listing decisions at the hospital /institutional level
- Explain how cost-effectiveness thresholds inform drug policy listing decisions
- Discuss the role of private listing agreements